Gonads are the heart of the matter

Menopause

Volumn 14, Issue 3, 2007, Pages 342-344

  Speroff, Leon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; SEX HORMONE; TESTOSTERONE;

AGING; CARDIOVASCULAR FUNCTION; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MENOPAUSE; METABOLISM; NOTE; PHYSIOLOGY; WOMEN'S HEALTH;

AGING; CARDIOVASCULAR PHYSIOLOGY; CORONARY DISEASE; ESTROGENS; FEMALE; GONADAL HORMONES; HUMANS; MENOPAUSE; TESTOSTERONE; WOMEN'S HEALTH;

EID: 34447277137     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31803816ec     Document Type: Editorial

References (36)

1. He H, Yang F, Liu X, et al. Sex hormone ratio changes in men and postmenopausal women with coronary artery disease. Menopause 2007;14:385-390.
2. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007;14:373-384.
3. Hamelin BA, Methot J, Arsenault M, et al. Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women. Am J Med 2003;114:599-602.
4. Matthews KA, Santoro N, Lasley B, et al. Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases. J Clin Endocrinol Metab 2006;91:1789-1795.
5. Rickenlund A, Eriksson MJ, Schenck-Gustafsson K, Hirschberg AL. Amenorrhea in female athletes is associated with endothelial dysfunction and unfavorable lipid profile. J Clin Endocrinol Metab 2005;90:1354-1359.
6. Rickenlund A, Eriksson MJ, Schenck-Gustafsson K, Hirschberg AL. Oral contraceptives improve endothelial function in amenorrheic athletes. J Clin Endocrinol Metab 2005;90:3162-3167.
7. Merz Bairey CN, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am College Cardiol 2003;41:413-419.
8. Kaplan JR, Adams MR, Anthony MS, Morgan TM, Manuck SB, Clarkson TB. Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Arterioscler Thromb Vasc Biol 1995;15:2094-2100.
9. Kaplan JR, Manuck SB, Anthony MS, Clarkson TB. Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys. Am J Obstet Gynecol 2002;99:381-388.
10. Clarkson TB, Appt S. Controversies about HRT-lessons from monkey models. Maturitas 2005;51:64-74.
11. Merz Bairey CN, Johnson BD, Berga SL, et al. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertil Steril 2006;85:1425-1431.
12. Hanke H, Hanke S, Ickrath O, et al. Estradiol concentrations in premenopausal women with coronary heart disease. Coron Artery Dis 1997;8:511-515.
13. Shively CA, Register TC, Friedman DP, Morgan TM, Thompson J, Lanaier T. Social stress-associated depression in adult female cynomolgus monkeys (Macaca fascicularis). Biol Psychol 2005;69:67-84.
14. Agatisa PK, Matthews KA, Bromberger JT, Edmundowicz D, Chang YF, Sutton-Tyrrell K. Coronary and aortic calcification in women with a history of major depression. Arch Intern Med 2005;165:1229-1236.
15. Clarkson TB, Anthony MS. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. Br J Obstet Gynaecol 1996;103(Suppl 13):53-57.
16. Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. Menopause 2005;12:366-373.
17. Mendelsohn MEK, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587.
18. Zhu X, Bonet B, Knopp RH. Estradiol 17beta inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees. Atherosclerosis 2000;148:31-41.
19. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-951.
20. Wild RA, Van Nort JJ, Grubb B, Bachman W, Hartz A, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990;54:255-259.
21. Graf MJ, Richards CJ, Brown V, Meissner L, Dunaif A. The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol 1990;33:119-131.
22. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol 1992;37:119-125.
23. Wild RA, Alaupovic P, Parker IJ. Lipid and apolipoprotein abnormalities in hirsute women. I The association with insulin resistance. Am J Obstet Gynecol 1992;166:1191-1196.
24. Talbott E, Guzick DS, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821-826.
25. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996;174:1224-1232.
26. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32-35.
27. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013-2017.
28. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-340.
29. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, Van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;90:2618-2623.
30. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91:843-850.
31. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64.
32. Lambrinoudaki I, Christodoulakos G, Rizos D, et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 2006;154:907-916.
33. Mudali S, Dobs AS, Ding J, et al. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol Metab 2005;90:1202-1209.
34. Bernini GP, Moretti A, Sgro M, et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001;8:43-50.
35. Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 2002;155:437-445.
36. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab 2005;90:2708-2711.